341 related articles for article (PubMed ID: 28131088)
1. Long-term passage of Vif-null HIV-1 in CD4
Miyagi E; Kao S; Fumitaka M; Buckler-White A; Plishka R; Strebel K
Virology; 2017 Apr; 504():1-11. PubMed ID: 28131088
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
3. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
4. APOBEC3 degradation is the primary function of HIV-1 Vif determining virion infectivity in the myeloid cell line THP-1.
Ikeda T; Shimizu R; Nasser H; Carpenter MA; Cheng AZ; Brown WL; Sauter D; Harris RS
mBio; 2023 Aug; 14(4):e0078223. PubMed ID: 37555667
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
[TBL] [Abstract][Full Text] [Related]
6. The Disassociation of A3G-Related HIV-1 cDNA G-to-A Hypermutation to Viral Infectivity.
Martin J; Chen X; Jia X; Shao Q; Liu B
Viruses; 2024 May; 16(5):. PubMed ID: 38793610
[TBL] [Abstract][Full Text] [Related]
7. The effect of HIV-1 Vif polymorphisms on A3G anti-viral activity in an in vivo mouse model.
Cadena C; Stavrou S; Manzoni T; Iyer SS; Bibollet-Ruche F; Zhang W; Hahn BH; Browne EP; Ross SR
Retrovirology; 2016 Jun; 13(1):45. PubMed ID: 27363431
[TBL] [Abstract][Full Text] [Related]
8. Identification of the HIV-1 Vif and Human APOBEC3G Protein Interface.
Letko M; Booiman T; Kootstra N; Simon V; Ooms M
Cell Rep; 2015 Dec; 13(9):1789-99. PubMed ID: 26628364
[TBL] [Abstract][Full Text] [Related]
9. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.
Casartelli N; Guivel-Benhassine F; Bouziat R; Brandler S; Schwartz O; Moris A
J Exp Med; 2010 Jan; 207(1):39-49. PubMed ID: 20038599
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Vif mRNA splicing by human immunodeficiency virus type 1 requires 5' splice site D2 and an exonic splicing enhancer to counteract cellular restriction factor APOBEC3G.
Mandal D; Exline CM; Feng Z; Stoltzfus CM
J Virol; 2009 Jun; 83(12):6067-78. PubMed ID: 19357165
[TBL] [Abstract][Full Text] [Related]
11. Translational regulation of APOBEC3G mRNA by Vif requires its 5'UTR and contributes to restoring HIV-1 infectivity.
Guerrero S; Libre C; Batisse J; Mercenne G; Richer D; Laumond G; Decoville T; Moog C; Marquet R; Paillart JC
Sci Rep; 2016 Dec; 6():39507. PubMed ID: 27996044
[TBL] [Abstract][Full Text] [Related]
12. An intronic G run within HIV-1 intron 2 is critical for splicing regulation of vif mRNA.
Widera M; Erkelenz S; Hillebrand F; Krikoni A; Widera D; Kaisers W; Deenen R; Gombert M; Dellen R; Pfeiffer T; Kaltschmidt B; Münk C; Bosch V; Köhrer K; Schaal H
J Virol; 2013 Mar; 87(5):2707-20. PubMed ID: 23255806
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in the APOBEC3G gene of Chinese rhesus macaques affect resistance to ubiquitination and degradation mediated by HIV-2 Vif.
Jiang ZQ; Yao XR; Yu H; Lu YE; Liu BL; Liu FL; Jin YB; Zhuo M; Zheng YT; Ling F
Arch Virol; 2019 May; 164(5):1353-1360. PubMed ID: 30859472
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of Vif proteins from HIV-1 infected patients with different APOBEC3G haplotypes.
Reddy K; Ooms M; Letko M; Garrett N; Simon V; Ndung'u T
AIDS; 2016 Jul; 30(11):1723-9. PubMed ID: 27064995
[TBL] [Abstract][Full Text] [Related]
15. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
[TBL] [Abstract][Full Text] [Related]
16. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 Vif Gained Breadth in APOBEC3G Specificity after Cross-Species Transmission of Its Precursors.
Chesarino NM; Emerman M
J Virol; 2022 Feb; 96(4):e0207121. PubMed ID: 34908448
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 restriction by endogenous APOBEC3G in the myeloid cell line THP-1.
Ikeda T; Molan AM; Jarvis MC; Carpenter MA; Salamango DJ; Brown WL; Harris RS
J Gen Virol; 2019 Jul; 100(7):1140-1152. PubMed ID: 31145054
[TBL] [Abstract][Full Text] [Related]
19. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.
Albin JS; Haché G; Hultquist JF; Brown WL; Harris RS
J Virol; 2010 Oct; 84(19):10209-19. PubMed ID: 20686027
[TBL] [Abstract][Full Text] [Related]
20. Moloney leukemia virus 10 (MOV10) inhibits the degradation of APOBEC3G through interference with the Vif-mediated ubiquitin-proteasome pathway.
Chen C; Ma X; Hu Q; Li X; Huang F; Zhang J; Pan T; Xia J; Liu C; Zhang H
Retrovirology; 2017 Dec; 14(1):56. PubMed ID: 29258557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
